Improving Smoking Cessation Quitlines: Pilot Study of Acceptance Therapy (TALK)

Fred Hutchinson Cancer Center (FHCC)

Status: Completed

Conditions: Smoking

Treatments: Behavioral: Acceptance Therapy (ACT); Other: Cognitive Behavioral Therapy (CBT)

Study type: Interventional

Funder types: Other; Industry

Identifiers

NCT01525420

7445 (Other Identifier)

Details and patient eligibility

About

The purpose of this study is to demonstrate that Acceptance Therapy (ACT's) implementation outcomes are at least as good as those of traditional cognitive behavioral therapy (CBT).

Implementation outcomes:

• end of treatment and 6-month follow-up data retention rates;
• intervention implementation quality;
• number & length of calls completed.

Comparison of each arm's implementation

Enrollment: 121 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

1. aged 18 and older;
2. smokes at least 10 cigarettes daily and has done so for at least the past 12 months;
3. wants to quit smoking in the next 30 days;
4. willing to be randomly assigned to either group;
5. willing and able to speak and read in English;
6. willing and medically eligible to use nicotine replacement therapy (NRT),
7. currently resides in the U.S., and expects to continue for at least 12 months;
8. not participating in other smoking cessation interventions;
9. has regular access to a telephone.
10. has regular access to an email address.

Exclusion criteria

• The Exclusion criteria are the opposite of the Inclusion criteria listed above. In addition, the following exclusion criteria also apply:

  1. another member of household enrolled in the study;
  2. currently using medication or nicotine replacement products to help with quitting smoking;
  3. currently using any non-cigarette tobacco products;
  4. pregnant or breastfeeding;
  5. had a heart attack in last 30 days;
  6. within the last 6 months, diagnosed with angina, heart pain, or irregular heartbeat;
  7. serious adverse reactions to nicotine patches including anaphylaxis and related symptoms such as hives, respiratory difficulty, and/or angioedema.

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Single Blind

---

121 participants in 2 patient groups

ACT

Experimental group

Description:

ACT: This is the experimental arm of the study. This included 5 weekly sessions of ACT therapy via telephone.

Treatment:

Behavioral: Acceptance Therapy (ACT)

CBT

Active Comparator group

Description:

CBT: This is the control arm of the study. This included 5 weekly sessions of CBT therapy via telephone.

Treatment:

Other: Cognitive Behavioral Therapy (CBT)